Comparison of a New Masterful Preparation to Kligman's Trio in the Treatment of Melasma

Phase 2CompletedNCT05119413

Centre Hospitalier Universitaire de Nice40 enrolled

Overview

Kligman's trio remains the gold standard treatment for melasma. It contain hydroquinone which is an effective anti-melanogenic compound but that has poor tolerance and numerous side-effects. Thiamidol has been proven to be at least as effective as hydroquinone and has a very good safety profile. The objective of this study is to compare the Kligman's trio to the same preparation in which hydroquinone is replaced by thiamidol.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Melanosis

Interventions

New trio de KligmanDRUG

Once daily application in addition to the same sunscreen

Trio KligmanDRUG

Once daily application in addition to the same sunscreen

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * SIGNED WRITTEN CONSENT 1) Melasma clinically diagnosed Exclusion Criteria: 1. Pregnant woman 2. Other pigmentary disorder affecting the face 3. Use of systemic or topical steroids or retinoids, use of topical depigmenting agents or depigmenting procedure in the month before the inclusion

Locations (1)

CHU de Nice

Nice, Alpes-maritimes, France

Outcomes

Primary Outcomes

The melasma's type

Clinical score MASI

Time frame: at 12 weeks

Secondary Outcomes

the Quality of life of patient

descriptive name of scale : meslascol

Time frame: at 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.